For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Theraclone Sciences, Inc.

USPTO Granted Patents = 28

% Expired Patents = 46.4

EPO Patents = 9

Forward Citations = 76

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Ole Olsen (24 out of 35 patents)

Matthew Moyle (22 out of 32 patents)

Jennifer L Mitcham (22 out of 60 patents)

4. Po-Ying Chan-Hui (16 out of 27 patents)

5. Steven Frey (15 out of 21 patents)

6. Sanjay K Phogat (14 out of 25 patents)

7. Dennis R Burton (14 out of 55 patents)

8. Pascal Raymond Georges Poignard (14 out of 16 patents)

9. Melissa Danielle De Jean De St Marcel Simek-Lemos (14 out of 14 patents)

10. Wayne C Koff (14 out of 25 patents)

11. Stephen Kaminsky (13 out of 19 patents)

12. Laura Marjorie Walker (10 out of 10 patents)

13. Andres G Grandea, Iii (8 out of 8 patents)

14. Thomas C Cox (7 out of 7 patents)

15. Katherine Doores (6 out of 6 patents)

Core Competencies:

HIV-1 Treatment

Monoclonal Antibodies

Influenza Therapy

Broadly Neutralizing Antibodies

Human Immunodeficiency Virus

Envelope Glycoprotein

Cytomegalovirus

Granulocyte-Macrophage Colony-Stimulating Factor

Human M2e Peptide Immunogens

Anti-Hemagglutinin Antibodies

Trimeric Forms

Viral Infections

28 patents: Sort by Forward Citations

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

3. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

4. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

5. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

6. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

7. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

8. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2020-11-17),

9. 10407493 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-09-10),

10. 10239934 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-03-26),

11. 10087239 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2018-10-02),

12. 9920111 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2018-03-20),

13. 9464131 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2016-10-11),

14. 9051362 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2015-06-09),

15. 8974788 - Compositions and methods for the therapy and diagnosis of influenza (2015-03-10),

Company Overview

Theraclone Sciences, Inc. is a biotechnology company based in Seattle, WA, focused on the discovery and development of innovative therapeutics. The company specializes in harnessing the power of monoclonal antibodies to address unmet medical needs, particularly in the fields of infectious diseases and oncology. Through its proprietary technologies, Theraclone aims to create novel treatments that can significantly improve patient outcomes and contribute to advancements in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

28 Patents

#82 in Seattle, WA

#272 in Washington

#12,009 in US

#23,262 in the World

Seattle, WA, United States of America

Theraclone Sciences, Inc.

Forward Citations = 76

20 inventors:

Ole Olsen (24 out of 35 patents)

Matthew Moyle (22 out of 32 patents)

Jennifer L Mitcham (22 out of 60 patents)

4. Po-Ying Chan-Hui (16 out of 27 patents)

5. Steven Frey (15 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Theraclone Sciences, Inc.. Retrieved from https://idiyas.com/company/theraclone-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…